Dianthus Therapeutics Inc <DNTH.O>: Wedbush raises target price to $122 from $105
DNTH•Related News
Kymera Therapeutics posts corporate deck outlining push to develop oral targeted protein degraders for immunology
KYMR•
Northrop Grumman <NOC.N>: Bernstein cuts target price to $653 from $660
NOC•
Rand Capital Q2 investment income falls on non-accruals
RAND•
Global Ship Lease 2Q26 net income falls 4.04% to USD 89.29 million; revenue rises 3.55% to USD 198.69 million
GSL•
Compass Pathways publishes investor presentation on COMP360 psilocybin program, FDA filing progress and launch plans
CMPS•